LIFE SCIENCES CONSULTING

The accelerated change that took place during the COVID-19 pandemic and the convergence of breakthrough scientific innovation, digital advancements, and new business models have reshaped the life sciences industry. These advancements offer promise for substantial improvement in patient care and have opened up new opportunities for players across the life sciences market landscape.

However, this evolving and increasingly competitive landscape has also raised several new challenges, including increased pricing pressure, uncertain market access dynamics, evolving consumer behavior, and disruption from nontraditional healthcare players. These trends are forcing life sciences companies to think strategically about which aspects of their current business they want to invest in and which new avenues of growth they will need to explore.

At TNG, we help life sciences and pharmaceutical executives develop practical strategies and plan to improve healthcare for patients and win in a dynamic global healthcare market.

How we support

Small, midsize, and large multinational life sciences companies routinely engage us to:

• Define and execute corporate strategy: We work closely with our clients to define and execute customized strategies to drive long-term, sustainable value. Whether it’s defining a new business model, driving growth beyond a first product, evaluating attractive adjacencies, determining how to scale the team, or building franchise leadership, our team has a proven track record of helping our clients build winning strategies unique to their circumstances.
   
• Expand into new markets: We help our clients expand into new geographies and market segments. This includes mature and emerging markets; prescription and consumer markets; primary and specialty care markets; chronic, acute and orphan markets; research, diagnostic and therapeutic markets; and new, innovative markets. Our market access strategies for clients open the door for growth and long-term value creation.

• Execute value-creating deals: We support our clients at every stage of the deal lifecycle — from search and evaluation to execution and post-transaction integration. We have helped our life sciences clients execute more than $140 billion worth of transactions including in-licensing, out-licensing, strategic partnerships, M&A, joint ventures, divestitures, and royalty monetization transactions.
   
• Launch innovative products and services: We team up with our clients to develop commercial launch strategies in mature and emerging markets. We have demonstrated success in supporting leading pharmaceutical, biotech, and device brands across all key regions. Our commercial planning and launch expertise include pharmaceutical and biopharmaceutical drugs, vaccines, life science tools, diagnostics, and life sciences enablers e.g., CROs/CDMOs.
   
• Optimize operations: We work closely with our clients to optimize operations, organizational structures, financials, and processes across the life sciences value chain. Our work for clients has increased productivity and contributed to top-and-bottom-line growth at the corporate, business unit, and operational team levels in a number of life sciences sectors.